A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS in England, the drugs spending watchdog says. Donanemab was hailed as a turning point in the disease last year. But the National Institute ...

The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for the disease safe for use but the rationing body has immediately ruled that it is too expensive for NHS patients.

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money - Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs